Price Target Increase#
Citizens has raised its price target for Intellia Therapeutics (NASDAQ: NTLA) from $28 to $30, while keeping a Market Outperform rating. Analyst Silvan Turkcan emphasized that recent data marks a significant achievement for Intellia and the broader gene-editing industry, as it successfully navigates a crucial clinical phase for its first in-vivo therapy.
Stock Performance#
Despite the positive news, Intellia's stock has seen a nearly 15% decline over the past week. However, it remains up 54% over the last year. The muted stock response is attributed to the upcoming launch needing to demonstrate the therapy's value. Current analysis suggests that NTLA may be undervalued, with potential for growth.
Valuation Insights#
Citizens has valued Intellia's hereditary angioedema (HAE) program at $18 per share, following encouraging results from Phase 3 trials. The stock closed around $13, and analysts believe there is substantial upside potential from the HAE program alone. Recent data shows that five analysts have increased their earnings forecasts for Intellia, indicating a positive outlook.
Recent Developments#
In addition to the price target adjustment, Intellia announced a $150 million public offering of common stock shares. The company plans to sell all shares and has given underwriters a 30-day option to purchase an additional 15%. This announcement coincides with the positive topline results from Intellia’s Phase 3 HAELO trial for its in vivo gene-editing therapy, lonvo-z, which successfully met both primary and secondary treatment goals for hereditary angioedema. Following these results, several analyst firms have adjusted their price targets, reflecting a generally optimistic sentiment about the company's future.